{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018413","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.648890+00:00","generated_at":"2026-06-05T20:44:01.935490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025","bullets":["Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.","Cash and investments $745M as of Jan 9, 2024, including $301M from equity offering; runway into H1 2027.","KT-474 Phase 2 trials in HS and AD started; topline data expected H1 2025; $55M milestone from Sanofi.","KT-621 STAT6 degrader Phase 1 expected H2 2024; KT-294 TYK2 Phase 1 expected H1 2025; data in 2025.","Additional Phase 1 data for KT-333 (STAT3) and KT-253 (MDM2) expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018413","json":"https://secwatch.observer/filing/0000950170-24-018413.json","markdown":"https://secwatch.observer/filing/0000950170-24-018413.md","text":"https://secwatch.observer/filing/0000950170-24-018413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/0000950170-24-018413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/kymr-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:44:01.935490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f079582c88e4ae3f66448323d220e44db9f4c921","claim":"Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/0000950170-24-018413-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}